Top

Published in:

01-04-2010 | Original Article

Cross-protection against influenza virus infection by intranasal administration of M2-based vaccine with chitosan as an adjuvant

Authors: Zhiwei Sui, Quanjiao Chen, Rui Wu, Hongbo Zhang, Mei Zheng, Hanzhong Wang, Ze Chen

Published in: Archives of Virology | Issue 4/2010

Abstract

Influenza vaccines based on conserved antigens could provide cross-protection against infections by multiple subtypes of influenza A virus. Influenza matrix protein 2 (M2) is highly conserved in all influenza A strains. In this study, we deleted the transmembrane domain of the M2 of the avian influenza virus (AIV) A/Chicken/Jiangsu/7/2002 (H9N2) strain to create an M2 without a transmembrane domain, named sM2, which was efficiently expressed in Escherichia coli. The sM2 protein was administered intranasally to mice in combination with chitosan adjuvant three times at an interval of 3 weeks. Three weeks after the last immunization, the mice were challenged with a lethal dose (5 × LD₅₀) of A/Chicken/Jiangsu/7/2002 (H9N2) virus, PR8 (H1N1) virus and A/Chicken/Henan/12/2004 (H5N1) virus. The protective immunity of the vaccine was evaluated by determining the survival rates, residual lung virus titers, body weight, and the serum antibody titers of the mice. Nasal administration of 15 μg sM2 in combination with chitosan completely protected mice against the homologous virus and protected 90 and 30% of the mice against the heterologous H1N1 and H5N1 viruses, respectively. The study indicated that the sM2 protein was a candidate antigen for a broad-spectrum influenza virus vaccine and that the adjuvant chitosan improved the efficacy of the sM2 vaccine.

Cox NJ, Subbarao K (1999) Influenza. Lancet 354:1277–1282CrossRefPubMed

De Filette M, Fiers W, Martens W et al (2006) Improved design and intranasal delivery of an M2e-based human influenza A vaccine. Vaccine 24:6597–6601CrossRefPubMed

Palese P (2004) Influenza: old and new threats. Nat Med 10:S82–S87CrossRefPubMed

Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Anderson LJ, Fukuda K (2003) Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 289:179–186CrossRefPubMed

Hilleman MR (2002) Realities and enigmas of human viral influenza: pathogenesis, epidemiology and control. Vaccine 20:3068–3087CrossRefPubMed

Okuda K, Ihata A, Watabe S et al (2001) Protective immunity against influenza A virus induced by immunization with DNA$ plasmid containing influenza M gene. Vaccine 19:3681–3691CrossRefPubMed

De Filette M, Ramne A, Birkett A et al (2006) The universal influenza vaccine M2e-HBc administered intranasally in combination with the adjuvant CTA1-DD provides complete protection. Vaccine 24:54451

Steinhauer DA, Skehel JJ (2002) Genetics of influenza viruses. Annu Rev Genet 36:305–332CrossRefPubMed

Chen Q, Kuang H, Wang H et al (2009) Comparing the ability of a series of viral protein-expressing plasmid DNAs to protect against H5N1 influenza virus. Virus Genes 38:30–38CrossRefPubMed

10.

Reid AH, Fanning TG, Janczewski TA et al (2002) Characterization of the 1918 “Spanish” influenza virus matrix gene segment. J Virol 76:10717–10723CrossRefPubMed

11.

Fiers W, De Filette M, Birkett A et al (2004) A “universal” human influenza A vaccine. Virus Res 103:173–176CrossRefPubMed

12.

Zebedee SL, Lamb RA (1988) Influenza A virus M2 protein: monoclonal antibody restriction of virus growth and detection of M2 in virions. J Virol 62:2762–2772PubMed

13.

Treanor JJ, Tierney EL, Zebedee SL et al (1990) Passively transferred monoclonal antibody to the M2 protein inhibits influenza A virus replication in mice. J Virol 64:1375–1377PubMed

14.

Fan J, Liang X, Horton MS et al (2004) Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys. Vaccine 22:2993–3003CrossRefPubMed

15.

Slepushkin VA, Katz JM, Black RA et al (1995) Protection of mice against influenza A virus challenge by vaccination with baculovirus-expressed M2 protein. Vaccine 13:1399–1402CrossRefPubMed

16.

Frace AM, Klimov AI, Rowe T et al (1999) Modified M2 proteins produce heterotypic immunity against influenza A virus. Vaccine 17:2237–2244CrossRefPubMed

17.

Neirynck S, Deroo T, Saelens X et al (1999) A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat Med 5:1157–1163CrossRefPubMed

18.

Mozdzanowska K, Feng J, Eid M et al (2003) Induction of influenza type A virus-specific resistance by immunization of mice with a synthetic multiple antigenic peptide vaccine that contains ectodomains of matrix protein 2. Vaccine 21:2616–2626CrossRefPubMed

19.

Watabe S, Xin KQ, Ihata A et al (2001) Protection against influenza virus challenge by topical application of influenza DNA vaccine. Vaccine 19:4434–4444CrossRefPubMed

20.

Tompkins SM, Zhao ZS, Lo CY et al (2007) Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1. Emerg Infect Dis 13:426–435CrossRefPubMed

21.

Brandtzaeg P (2003) Role of mucosal immunity in influenza. Dev Biol (Basel) 115:39–48

22.

Zuercher AW, Coffin SE, Thurnheer MC et al (2002) Nasal-associated lymphoid tissue is a mucosal inductive site for virus-specific humoral and cellular immune responses. J Immunol 168:1796–1803PubMed

23.

Russell MW, Moldoveanu Z, White PL et al (1996) Salivary, nasal, genital, and systemic antibody responses in monkeys immunized intranasally with a bacterial protein antigen and the Cholera toxin B subunit. Infect Immun 64:1272–1283PubMed

24.

Muszkat M, Friedman G, Schein MH et al (2000) Local SIgA response following administration of a novel intranasal inactivated influenza virus vaccine in community residing elderly. Vaccine 18:1696–1699CrossRefPubMed

25.

Hirabayashi Y, Kurata H, Funato H et al (1990) Comparison of intranasal inoculation of influenza HA vaccine combined with cholera toxin B subunit with oral or parenteral vaccination. Vaccine 8:243–248CrossRefPubMed

26.

Garmise RJ, Mar K, Crowder TM et al (2006) Formulation of a dry powder influenza vaccine for nasal delivery. AAPS PharmSciTech 7:E19CrossRefPubMed

27.

Bergquist C, Johansson EL, Lagergard T et al (1997) Intranasal vaccination of humans with recombinant cholera toxin B subunit induces systemic and local antibody responses in the upper respiratory tract and the vagina. Infect Immun 65:2676–2684PubMed

28.

Xie Y, Zhou NJ, Gong YF et al (2007) Th immune response induced by H. pylori vaccine with chitosan as adjuvant and its relation to immune protection. World J Gastroenterol 13:1547–1553PubMed

29.

Mutsch M, Zhou W, Rhodes P et al (2004) Use of the inactivated intranasal influenza vaccine and the risk of Bell’s palsy in Switzerland. N Engl J Med 350:896–903CrossRefPubMed

30.

van Ginkel FW, Jackson RJ, Yuki Y et al (2000) Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues. J Immunol 165:4778–4782PubMed

31.

Synowiecki J, Al-Khateeb NA (2003) Production, properties, and some new applications of chitin and its derivatives. Crit Rev Food Sci Nutr 43:145–171CrossRefPubMed

32.

Bacon A, Makin J, Sizer PJ et al (2000) Carbohydrate biopolymers enhance antibody responses to mucosally delivered vaccine antigens. Infect Immun 68:5764–5770CrossRefPubMed

33.

Jabbal-Gill I, Fisher AN, Rappuoli R et al (1998) Stimulation of mucosal and systemic antibody responses against Bordetella pertussis filamentous haemagglutinin and recombinant pertussis toxin after nasal administration with chitosan in mice. Vaccine 16:2039–2046CrossRefPubMed

34.

McNeela EA, O’Connor D, Jabbal-Gill I et al (2000) A mucosal vaccine against diphtheria: formulation of cross reacting material (CRM(197)) of diphtheria toxin with chitosan enhances local and systemic antibody and Th2 responses following nasal delivery. Vaccine 19:1188–1198CrossRefPubMed

35.

Westerink MA, Smithson SL, Srivastava N et al (2001) ProJuvant (Pluronic F127/chitosan) enhances the immune response to intranasally administered tetanus toxoid. Vaccine 20:711–723CrossRefPubMed

36.

Read RC, Naylor SC, Potter CW et al (2005) Effective nasal influenza vaccine delivery using chitosan. Vaccine 23:4367–4374CrossRefPubMed

37.

Illum L (1998) Chitosan and its use as a pharmaceutical excipient. Pharm Res 15:1326–1331CrossRefPubMed

38.

Singla AK, Chawla M (2001) Chitosan: some pharmaceutical and biological aspects—an update. J Pharm Pharmacol 53:1047–1067CrossRefPubMed

39.

Wedmore I, McManus JG, Pusateri AE et al (2006) A special report on the chitosan-based hemostatic dressing: experience in current combat operations. J Trauma 60:655–658CrossRefPubMed

40.

Zaharoff DA, Rogers CJ, Hance KW et al (2007) Chitosan solution enhances both humoral and cell-mediated immune responses to subcutaneous vaccination. Vaccine 25:2085–2094CrossRefPubMed

41.

Qiu M, Fang F, Chen Y et al (2006) Protection against avian influenza H9N2 virus challenge by immunization with hemagglutinin- or neuraminidase-expressing DNA in BALB/c mice. Biochem Biophys Res Commun 343:1124–1131CrossRefPubMed

42.

Yetter RA, Lehrer S, Ramphal R et al (1980) Outcome of influenza infection: effect of site of initial infection and heterotypic immunity. Infect Immun 29:654–662PubMed

43.

Tamura S, Ito Y, Asanuma H et al (1992) Cross-protection against influenza virus infection afforded by trivalent inactivated vaccines inoculated intranasally with cholera toxin B subunit. J Immunol 149:981–988PubMed

44.

Chen Z, Sahashi Y, Matsuo K et al (1998) Comparison of the ability of viral protein-expressing plasmid DNAs to protect against influenza. Vaccine 16:1544–1549CrossRefPubMed

45.

Chen J, Fang F, Li X et al (2005) Protection against influenza virus infection in BALB/c mice immunized with a single dose of neuraminidase-expressing DNAs by electroporation. Vaccine 23:4322–4328CrossRefPubMed

46.

Liu W, Zou P, Chen YH (2004) Monoclonal antibodies recognizing EVETPIRN epitope of influenza A virus M2 protein could protect mice from lethal influenza A virus challenge. Immunol Lett 93:131–136CrossRefPubMed

47.

Chen J, Zhang F, Fang F et al (2007) Vaccination with hemagglutinin or neuraminidase DNA protects BALB/c mice against influenza virus infection in presence of maternal antibody. BMC Infect Dis 7:118CrossRefPubMed

48.

Zhang F, Chen J, Fang F et al (2005) Maternal immunization with both hemagglutinin- and neuraminidase-expressing DNAs provides an enhanced protection against a lethal influenza virus challenge in infant and adult mice. DNA Cell Biol 24:758–765CrossRefPubMed

49.

Illum L, Jabbal-Gill I, Hinchcliffe M et al (2001) Chitosan as a novel nasal delivery system for vaccines. Adv Drug Deliv Rev 51:81–96CrossRefPubMed

50.

Zhu B, Qie Y, Wang J et al (2007) Chitosan microspheres enhance the immunogenicity of an Ag85B-based fusion protein containing multiple T-cell epitopes of Mycobacterium tuberculosis. Eur J Pharm Biopharm 66:318–326CrossRefPubMed

Title: Cross-protection against influenza virus infection by intranasal administration of M2-based vaccine with chitosan as an adjuvant
Authors: Zhiwei Sui
Quanjiao Chen
Rui Wu
Hongbo Zhang
Mei Zheng
Hanzhong Wang
Ze Chen
Publication date: 01-04-2010
Publisher: Springer Vienna
Published in: Archives of Virology / Issue 4/2010
Print ISSN: 0304-8608
Electronic ISSN: 1432-8798
DOI: https://doi.org/10.1007/s00705-010-0621-4

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Cross-protection against influenza virus infection by intranasal administration of M2-based vaccine with chitosan as an adjuvant

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2010

Antigenic variation between Newcastle disease viruses of goose and chicken origin

An HDAC inhibitor increases AcMNPV gene expression in mammalian cells

First infectious clone of the propagatively transmitted Oat blue dwarf virus

Identification of SARS-like coronaviruses in horseshoe bats (Rhinolophus hipposideros) in Slovenia

Phylogenetic analysis of bovine leukemia viruses isolated in South America reveals diversification in seven distinct genotypes

Complete genomic sequence of a Tobacco rattle virus isolate from Michigan-grown potatoes

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page